\-\ Texto\\:\\ \ \(0\)\
\-\ swelling\\ and\\ edema\\ in\\ the\\ left\\ periorbital\\ region\\ with\\ a\\ depressed\\ globe\\ \\(enophthalmos\\)\\.\ \(0\)\
\-\ because\\ of\\ the\\ damage\\ from\\ rupture\\,\\ the\\ patient\\ had\\ an\\ enucleation\\ of\\ the\\ left\\ globe\\.\ \(0\)\
\-\ \\Â\\»\\ abnormal\\ morphology\\ and\\ contour\\ of\\ the\\ left\\ globe\\ with\\ associated\\ hemorrhage\ \(0\)\
\-\ \\Â\\»\\ abnormal\\ increased\\ attenuation\\ o\\.s\\.\ \(0\)\
\-\ \\Â\\»\\ fractures\\ left\\ orbit\\-\\ lateral\\,\\ posterior\\,\\ and\\ inferior\\ \\ walls\ \(0\)\
\-\ \\Â\\»\\ air\\ fluid\\ level\\ within\\ the\\ left\\ maxillary\\ sinus\ \(0\)\
\-\ rupture\\ of\\ the\\ left\\ globe\\ with\\ associated\\ orbital\\ wall\\ fractures\\.\ \(0\)\
\-\ blow\\-out\\ fracture\ \(2\)\
\-\ globe\\ rupture\ \(1\)\
\-\ globe\\ hemorrhage\ \(0\)\
\-\ ocular\\ tumor\ \(1\)\
\-\ presented\\ to\\ the\\ emergency\\ department\\ after\\ being\\ hit\\ in\\ the\\ face\\ by\\ a\\ softball\\.\ \(0\)\
\-\ with\\ rupture\\ of\\ the\\ globe\\,\\ this\\ patient\\ is\\ at\\ risk\\ for\\ sympathetic\\ ophthalmia\\.\\ \\ this\\ is\\ a\\ potentially\\ blinding\\ immune\\ mediated\\,\\ inflammatory\\ condition\\,\\ which\\ usually\\ follows\\ severe\\ trauma\\ to\\ one\\ eye\\.\\ the\\ mechanism\\ of\\ injury\\ must\\ be\\ a\\ traumatic\\ penetrating\\ or\\ rupturing\\ injury\\ to\\ the\\ eye\\ involving\\ the\\ region\\ of\\ the\\ ciliary\\ body\\.\\ \\ the\\ immune\\ system\\ becomes\\ exposed\\ to\\ antigens\\ in\\ the\\ eye\\ it\\ has\\ never\\ responded\\ to\\ before\\.\\ this\\ immune\\ system\\ reaction\\ can\\ then\\ result\\ in\\ complete\\ vision\\ loss\\ of\\ the\\ un\\-injured\\ eye\\.\ \(0\)\
\-\ treatment\\:\\ early\\ enucleation\\ within\\ two\\ weeks\\ of\\ injury\\ can\\ be\\ protective\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ globe\\:\\ 0\\.16630428591289512\ \(0\)\
\-\ immune\\:\\ 0\\.0815314479622586\ \(0\)\
\-\ \\Â\\»\\:\\ 0\\.08058082752111782\ \(0\)\
\-\ rupture\\:\\ 0\\.06943794484451182\ \(0\)\
\-\ eye\\:\\ 0\\.06860114463372079\ \(0\)\
\-\ enucleation\\:\\ 0\\.05618257841913931\ \(0\)\
\-\ orbit\\-\\:\\ 0\\.042179513990270326\ \(0\)\
\-\ ophthalmia\\:\\ 0\\.042179513990270326\ \(0\)\
\-\ blinding\\:\\ 0\\.042179513990270326\ \(0\)\
\-\ un\\-injured\\:\\ 0\\.042179513990270326\ \(0\)\
\-\ injury\\:\\ 0\\.03910347189314067\ \(0\)\
\-\ mediated\\:\\ 0\\.03886302030338063\ \(0\)\
\-\ rupturing\\:\\ 0\\.03886302030338063\ \(0\)\
\-\ o\\.s\\:\\ 0\\.03692299586267171\ \(0\)\
\-\ softball\\:\\ 0\\.03447885412216458\ \(0\)\
\-\ antigens\\:\\ 0\\.03447885412216458\ \(0\)\
\-\ blow\\-out\\:\\ 0\\.033606502175782024\ \(0\)\
\-\ enophthalmos\\:\\ 0\\.03286893911440758\ \(0\)\
\-\ ciliary\\:\\ 0\\.03286893911440758\ \(0\)\
\-\ protective\\:\\ 0\\.03286893911440758\ \(0\)\
\-\ system\\:\\ 0\\.032195980577998065\ \(0\)\
\-\ exposed\\:\\ 0\\.0316664777350731\ \(0\)\
\-\ fractures\\:\\ 0\\.03096448419119881\ \(0\)\
\-\ responded\\:\\ 0\\.029907029026339526\ \(0\)\
\-\ sympathetic\\:\\ 0\\.028349984048183414\ \(0\)\
\-\ left\\:\\ 0\\.027447998160944922\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.027217766355751537\ \(0\)\
\-\ periorbital\\:\\ 0\\.027177149320752863\ \(0\)\
\-\ depressed\\:\\ 0\\.025748953203260056\ \(0\)\
\-\ ocular\\:\\ 0\\.024774795522679964\ \(0\)\
\-\ morphology\\:\\ 0\\.024411226589771243\ \(0\)\
\-\ hit\\:\\ 0\\.02429592729991928\ \(0\)\
\-\ penetrating\\:\\ 0\\.024073343493053765\ \(0\)\
\-\ never\\:\\ 0\\.024073343493053765\ \(0\)\
\-\ potentially\\:\\ 0\\.023965817866967363\ \(0\)\
\-\ abnormal\\:\\ 0\\.023321456845118767\ \(0\)\
\-\ region\\:\\ 0\\.023096662461620215\ \(0\)\
\-\ maxillary\\:\\ 0\\.022355902859210363\ \(0\)\
\-\ follows\\:\\ 0\\.021990481908087996\ \(0\)\
\-\ damage\\:\\ 0\\.021851785559412147\ \(0\)\
\-\ becomes\\:\\ 0\\.021395755990970402\ \(0\)\
\-\ mechanism\\:\\ 0\\.021036735962535406\ \(0\)\
\-\ walls\\:\\ 0\\.02086684750101909\ \(0\)\
\-\ face\\:\\ 0\\.020050457467379074\ \(0\)\
\-\ contour\\:\\ 0\\.01982148128949565\ \(0\)\
\-\ orbital\\:\\ 0\\.019393992771142305\ \(0\)\
\-\ associated\\:\\ 0\\.01929629245844691\ \(0\)\
\-\ vision\\:\\ 0\\.018889875471344093\ \(0\)\
\-\ must\\:\\ 0\\.018638935397791257\ \(0\)\
\-\ reaction\\:\\ 0\\.018569590865243093\ \(0\)\
\-\ can\\:\\ 0\\.01854758232027818\ \(0\)\
\-\ department\\:\\ 0\\.018334506230900296\ \(0\)\
\-\ before\\:\\ 0\\.017306322453113265\ \(0\)\
\-\ traumatic\\:\\ 0\\.017124767756634206\ \(0\)\
\-\ condition\\:\\ 0\\.01709938473161175\ \(0\)\
\-\ attenuation\\:\\ 0\\.016438378327397314\ \(0\)\
\-\ result\\:\\ 0\\.015685091660038095\ \(0\)\
\-\ within\\:\\ 0\\.01559934362091944\ \(0\)\
\-\ emergency\\:\\ 0\\.015482242095599405\ \(0\)\
\-\ sinus\\:\\ 0\\.014952913730346592\ \(0\)\
\-\ early\\:\\ 0\\.014952913730346592\ \(0\)\
\-\ risk\\:\\ 0\\.014809601183536298\ \(0\)\
\-\ then\\:\\ 0\\.01455008075800043\ \(0\)\
\-\ complete\\:\\ 0\\.014389358535818441\ \(0\)\
\-\ involving\\:\\ 0\\.014346446239250209\ \(0\)\
\-\ because\\:\\ 0\\.014303915390363865\ \(0\)\
\-\ being\\:\\ 0\\.014247789362682096\ \(0\)\
\-\ inflammatory\\:\\ 0\\.014178545187521645\ \(0\)\
\-\ inferior\\:\\ 0\\.013872327087842405\ \(0\)\
\-\ air\\:\\ 0\\.013833792471540507\ \(0\)\
\-\ this\\:\\ 0\\.01379622794230813\ \(0\)\
\-\ swelling\\:\\ 0\\.013621104612349916\ \(0\)\
\-\ body\\:\\ 0\\.013278773744923849\ \(0\)\
\-\ be\\:\\ 0\\.012610112185109369\ \(0\)\
\-\ severe\\:\\ 0\\.012580429665387579\ \(0\)\
\-\ usually\\:\\ 0\\.012415924659649564\ \(0\)\
\-\ loss\\:\\ 0\\.011868249629035595\ \(0\)\
\-\ wall\\:\\ 0\\.011842866604013139\ \(0\)\
\-\ level\\:\\ 0\\.011784158027018812\ \(0\)\
\-\ two\\:\\ 0\\.011709718840267969\ \(0\)\
\-\ fluid\\:\\ 0\\.011620282797147621\ \(0\)\
\-\ weeks\\:\\ 0\\.011604199793785398\ \(0\)\
\-\ edema\\:\\ 0\\.011564227222159286\ \(0\)\
\-\ the\\:\\ 0\\.011245157129003055\ \(0\)\
\-\ trauma\\:\\ 0\\.011181860199798704\ \(0\)\
\-\ presented\\:\\ 0\\.011145251842212484\ \(0\)\
\-\ one\\:\\ 0\\.011080054465601168\ \(0\)\
\-\ fracture\\:\\ 0\\.010780259953458271\ \(0\)\
\-\ to\\:\\ 0\\.010216940393372877\ \(0\)\
\-\ increased\\:\\ 0\\.010002319530141893\ \(0\)\
\-\ tumor\\:\\ 0\\.009532211969429718\ \(0\)\
\-\ posterior\\:\\ 0\\.009424107888528462\ \(0\)\
\-\ it\\:\\ 0\\.009190662126952232\ \(0\)\
\-\ lateral\\:\\ 0\\.008835732275715552\ \(0\)\
\-\ had\\:\\ 0\\.008822247938950757\ \(0\)\
\-\ after\\:\\ 0\\.008459335897651686\ \(0\)\
\-\ treatment\\:\\ 0\\.008275679232540129\ \(0\)\
\-\ patient\\:\\ 0\\.00819705197049175\ \(0\)\
\-\ in\\:\\ 0\\.008065018758665166\ \(0\)\
\-\ \\,\\:\\ 0\\.007771580828247485\ \(0\)\
\-\ has\\:\\ 0\\.0076779902894463055\ \(0\)\
\-\ which\\:\\ 0\\.007632270752356692\ \(0\)\
\-\ a\\:\\ 0\\.0075904268290641385\ \(0\)\
\-\ by\\:\\ 0\\.006807994752367821\ \(0\)\
\-\ from\\:\\ 0\\.0060595010198766135\ \(0\)\
\-\ an\\:\\ 0\\.005653898872175741\ \(0\)\
\-\ at\\:\\ 0\\.005539536616419296\ \(0\)\
\-\ \\:\\:\\ 0\\.005408013473639546\ \(0\)\
\-\ is\\:\\ 0\\.0053807729988968956\ \(0\)\
\-\ of\\:\\ 0\\.005016910082210028\ \(0\)\
\-\ or\\:\\ 0\\.004791974875424438\ \(0\)\
\-\ for\\:\\ 0\\.003488555735132608\ \(0\)\
\-\ \\(\\:\\ 0\\.0034562762021237343\ \(0\)\
\-\ \\)\\:\\ 0\\.0034140559431258617\ \(0\)\
\-\ and\\:\\ 0\\.0025838613262997865\ \(0\)\
\-\ with\\:\\ 0\\.0022393143749261193\ \(0\)\
\-\ \\.\\:\\ 0\\.0018683966367024354\ \(0\)\
